IDEXX Laboratories Inc

Explore IDEXX Laboratories’ mixed analyst outlook, investor moves, and aging‑pet market opportunities in our in‑depth corporate analysis.

Idexx Laboratories Q4 2025 results show 13% revenue growth and $121M net income, but shares fell 6% amid valuation and regulatory concerns.

Institutional investors back IDEXX Laboratories as its blood‑gas analyzers meet rising clinical demand, offering high‑throughput, cost‑effective diagnostics for hospitals.

IDEXX Laboratories sees rising institutional buy‑in and strong margins as it expands its blood‑gas analyzer business, tackles supply‑chain risks, and adds AI‑driven services for global growth.

IDEXX Labs names Michael Erickson CEO, aiming for continuity while boosting AI‑driven veterinary diagnostics and global growth amid evolving regulation and cyber risks.

Idexx Laboratories Inc. to report 2025 Q4 and full‑year results Feb 2 2026, with a detailed analyst call covering revenue growth, margins, and 2026 guidance—key data for investors and veterinary leaders.

Idexx Laboratories: steady earnings, cutting‑edge veterinary diagnostics, robust safety and FDA/EMA‑approved products that slash turnaround times and boost pet‑care efficiency.

Explore how Idexx Laboratories’ AI‑driven veterinary diagnostics are reshaping pet health, driving revenue growth, and influencing market value.

Explore IDEXX Labs’ strategic growth: AI‑enabled diagnostics, strong subscription revenue, and global lab scale set to boost profitability and market share.

Idexx Laboratories: A deep dive into its veterinary diagnostics dominance, growth prospects in poultry and point‑of‑care markets, and the regulatory, data‑privacy, and sustainability challenges shaping its future.